Title:
CLD PROTEIN MUTANT AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/284889
Kind Code:
A1
Abstract:
The present application relates to the field of genetic engineering, specifically to a CLD protein mutant and the use thereof. The CLD protein mutant is as shown in SEQ ID NO. 4. According to the present invention, cysteine at position 60 of CD4 in a primary CLD recombinant protein is mutated into serine, and the ability of the obtained CLD protein mutant to inhibit a tested HIV-1 strain is increased by 2-3 orders of magnitude, significantly improving the ability to neutralize the virus; and this difference is more significant in the tested HIV-1T/F (transmitter/founder) virus. The CLD protein can greatly improve the binding efficiency with the HIV-1 virus; and a complex formed by the CLD protein mutant or the recombinant CLD protein and an envelope protein can be used as an immunogen to better induce an antibody against V1 and V2 regions of the envelope protein, thus exhibiting good application prospects.
More Like This:
Inventors:
HU QINXUE (CN)
FU MING (CN)
DU TAO (CN)
FU MING (CN)
DU TAO (CN)
Application Number:
PCT/CN2022/113737
Publication Date:
January 19, 2023
Filing Date:
August 19, 2022
Export Citation:
Assignee:
CHENGDU VIROGEN BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
C07K19/00; A61K38/17; A61K39/21; A61P31/18
Foreign References:
| CN113563480A | 2021-10-29 | |||
| CN106701692A | 2017-05-24 | |||
| CN102617738A | 2012-08-01 |
Other References:
DATABASE PROTEIN ANONYMOUS : "Chain A, gp120", XP093024028, retrieved from NCBI
Attorney, Agent or Firm:
UNI-INTEL PATENT AND TRADEMARK LAW FIRM (CN)
Download PDF: